Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. - Wikidata - awgldk - TriplyDB

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

http://www.wikidata.org/entity/Q36735206

about

Targeted therapies in sarcomas: challenging the challenge Hepatic falciform ligament clear cell myomelanocytic tumor: A case report and a comprehensive review of the literature on perivascular epithelioid cell tumors Malignant perivascular epithelioid cell tumor (PEComa) of the femur: a case report and literature review Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Response and acquired resistance to everolimus in anaplastic thyroid cancer Treatment of Adult Soft Tissue Sarcomas: An Overview High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing The evolution of systemic therapy in sarcoma.Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.mTORC1 activation in childhood ependymoma and response to sirolimus.Malignant PEComa: a case report with emphasis on clinical and morphological criteria.Metastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition.A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.New therapeutic targets in soft tissue sarcoma.Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model Malignant perivascular epithelioid cell tumor (PEComa) of cervix with TFE3 gene rearrangement: a case report.Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.Perivascular epithelioid cell neoplasm of the uterine cervix: an unusual tumor in an unusual location.Emerging therapies for adult soft tissue sarcoma.Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.The off-label use of targeted therapies in sarcomas: the OUTC'S program Pancreatic perivascular epithelioid cell tumour presenting with upper gastrointestinal bleeding.PEComa in a Young Patient with Known Li-Fraumeni Syndrome.A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report.Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Targeted therapy in sarcomas other than GIST tumors Primary malignant gastric PEComa - Diagnostic and technical dilemmas Malignant perivascular epithelioid cell tumor arising in the mesentery: A case report The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.Pancreatic perivascular epithelioid cell tumor: A case report with clinicopathological features and a literature review.Advances in sarcoma genomics and new therapeutic targets.Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma.Lymphangioleiomyomatosis - a wolf in sheep's clothing.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Multimodality therapy for metastatic sarcomas confined to the lung.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.

P2860

Q21285014-78C2FF46-7280-4326-B38A-455CCC9B3C9E Q26772169-B3DD2551-4992-475E-80CF-4E44AD9A855A Q27030897-2533C23D-CAD5-4093-B049-3A1E66A1384A Q27852954-E01275BD-E2E4-44A0-87DB-3A79515CE7F7 Q27853080-0D542B76-9EE3-4496-9F3B-DBAB5BD33F30 Q28088685-0CEF0DFB-D6C8-418C-828C-9EC334BA578D Q30514084-82DFF586-CB82-4BAE-9DE9-3DE5343D7B4C Q33274710-F4B476FD-5908-4D31-926E-2E7F221550EE Q33416342-20BCE1AC-17FA-4208-B854-CD92A979E10E Q33746501-DC0B6FA4-8FFA-4307-BD20-6B7400BA00A4 Q33805499-1E95BA36-CB1A-4C10-BAB0-D00BE8BAC86E Q33841595-B0979AD5-0FD9-474A-ACEA-95E793A66894 Q33977969-15D2D4E2-6F7C-4812-AC96-C8C3AD472FF2 Q34267924-FEE14170-861B-487D-9BDD-58C3EFBE777E Q34325616-8CD17FA1-0C7E-49AA-B224-448ED4D8A69E Q34371874-CDCE869D-9F51-48F2-87FE-5BC5BA2EA62C Q34450447-107467E8-ED1D-480D-9C23-7BBD39B401BB Q34483290-D4847429-5D28-4189-874B-F112D90D7E5F Q34659806-F8E665D2-CB39-4637-8A69-A4C441AD66C7 Q34664479-7F418819-3DED-420B-AD31-452DD7567933 Q34795914-B437DF8A-BB8B-4D2B-A356-04078E831EA3 Q34897996-C0782BF7-26FC-437A-A4E5-FB20DEC202CF Q34997300-1C0968C3-E446-4095-858C-48E81773B904 Q35189626-59495C53-559E-4E40-B84C-29121E439287 Q35203838-7AD7744E-6CF1-4F85-A8AB-8FF6E3411C58 Q35606985-D27D3E1B-AC3D-4978-9CF0-0638F722130E Q35616803-3FBB4F5B-DD51-48A9-A44D-E81EBEFAC986 Q35622367-2B8B7F17-F988-4478-9881-EB15C142DC00 Q35701882-6126E8F2-B154-4C9F-B3F6-0569457F4350 Q35742194-DDCFC53F-CE9A-4F98-979B-A1257D4BBAA8 Q35918797-BD57CB89-5E96-4426-8503-134DF5F4587C Q35955322-5768A702-F05F-4F65-98E4-40D832974E9E Q35982066-BE433114-CB0C-4375-9C5E-23AF8EF80428 Q35993346-E17A36E9-D497-467A-AFE1-8A1613565CFD Q36144210-F69D70D1-D956-4782-9FC0-7FD51A008984 Q36190182-D06C43C2-6B1C-40A3-ABC1-DB72BAEAE0E8 Q36357766-FFEC839D-1476-4ED7-9994-EB84CEE319FC Q36389964-E2E70E0F-F5B5-479A-96AF-67999BB05F16 Q36424138-2CDBD776-746F-46DB-B3E1-E9E2170C253B Q36444369-F6AF4C4C-DA67-434D-97D4-37D19F66BCD1

P2860

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

http://www.wikidata.org/entity/Q36735206

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@ast

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@en

type

label

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@ast

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@en

prefLabel

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@ast

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@en

P1433

Q36735206-56B1392A-FA44-4F25-8FE4-891471CB5745

P1476

Q36735206-E347A95B-0047-4B9F-9F57-1AD9E3FEC387

P2093

Q36735206-0954F287-E952-4624-9B2B-5EF879215069

Q36735206-14CA2695-01D8-4CF3-A24E-E16F3F72F5B7

Q36735206-2F33E5E3-862D-44B0-A245-A848556FAB31

Q36735206-422F1821-4473-4E90-A685-2743439DFC87

Q36735206-4C72D9E0-987F-43A9-84C8-D39E3FC6B725

Q36735206-5E609ECF-F9F0-42BD-B550-31E660052C16

Q36735206-6875065D-5265-461A-AA9A-B8077578F2B3

Q36735206-7174AB2A-B4D8-469C-A4F8-51772B9222CD

Q36735206-8EBF8863-89EE-48F0-91F7-7D2ACFAA4E80

Q36735206-CE81A07B-A1EE-4346-9DAC-C8F72795D213

P2860

Q36735206-0F19F90E-E098-4ED3-B577-1BDB4A3C4C28

Q36735206-2B9B7DE8-73BC-4A39-9755-64400DC8E03E

Q36735206-36304812-E72A-496C-8F0B-CFC96433C453

Q36735206-4F7B470B-095B-4A17-B22D-2CAB5A4DB04A

Q36735206-5C629898-FB0E-4B80-AE62-E687AC0409A5

Q36735206-5E197811-56E7-445E-BC3C-05C00F43AA89

Q36735206-82829C7A-E0F5-4D60-83AB-D97777BCF1FE

Q36735206-9F89B177-330E-4135-A937-84499FDE326A

Q36735206-AEE08AFA-B7D1-4419-B53B-03F9321E6857

Q36735206-E191102C-9270-4595-9C4F-020F24C8B11F

P304

Q36735206-412DC161-F753-465B-8FFC-8F9EA2213CBA

P31

Q36735206-317942C9-A652-4844-B88E-440C28B6546A

P356

Q36735206-0D18ED9D-5DDA-4D1B-A2DB-7C8DAC061604

P407

Q36735206-F3DB672A-5670-426F-910F-B45270D459D1

P433

Q36735206-503EA2BF-5D5F-4366-9F31-726CC7BEADBF

P478

Q36735206-882DC2DC-6207-4B87-B3A3-25DF6D19ECE0

P577

Q36735206-57C6B6B7-BBC1-4BD5-B6B7-4BB8EF5F47ED

P5875

Q36735206-E0665418-E444-4A38-B3DB-EDA6074EAA4C

P698

Q36735206-C48B05BA-D98B-474F-8CD6-9933F9071D61

P932

Q36735206-5E1FFC89-737D-42AA-9DD7-48E071201FAE

P356

JCO.2009.25.2981

P1433

Journal of Clinical Oncology

P1476

Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.

@en

P2093

Andrew J Wagner

http://www.w3.org/2001/XMLSchema#string

Azra H Ligon

http://www.w3.org/2001/XMLSchema#string

Christopher D M Fletcher

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

David J Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Izabela Malinowska-Kolodziej

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Morgan

http://www.w3.org/2001/XMLSchema#string

Natalie Vena

http://www.w3.org/2001/XMLSchema#string

Nikhil H Ramaiya

http://www.w3.org/2001/XMLSchema#string

P2860

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.

Perivascular epithelioid cell neoplasms: pathology and pathogenesis.

PEComa: what do we know so far?

Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs.

Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.

P304

835-840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.2981

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40847063

http://www.w3.org/2001/XMLSchema#string

P698

20048174

http://www.w3.org/2001/XMLSchema#string

P932

4810029

http://www.w3.org/2001/XMLSchema#string